NFKB1 and acute myeloid leukemia: While AML cells may activate NFκB beyond the normal limits that are dictated by tissue function, their constitutive secretion of inflammatory mediators can lead to the inhibition of NFκB in immune cells, due to physiological negative feedback, impairing T-cell effector function [190].